What is the current Price Target for the ACELYRIN stock?

The average ACELYRIN target price is $10.00. This is 207.69% higher than the current stock price. The highest price target is 515.38%, the lowest is 53.85%. 6 Analysts have issued a price target ACELYRIN 2025 .

How high will the ACELYRIN stock rise?

No reliable answer can be given as to how high the ACELYRIN stock will rise. The performance of stocks, including the ACELYRIN stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the ACELYRIN stock today?

The performance of ACELYRIN stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the ACELYRIN stock fall?

The decline in ACELYRIN stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

ACELYRIN Forecast, price target & analysts

$3.09

5.08% today

NYSE, Dec 30, 09:21 pm CET

ISIN

US00445A1007

Symbol

SLRN

Reports

Quarter | Annual

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

ACELYRIN Target price 2024 - Analyst rating & recommendation

ACELYRIN Classifications & Recommendation:

Buy

57%

Hold

43%

ACELYRIN Price Target

Target Price	$10.00
Price	$3.25
Potential	207.69% register free of charge
Number of Estimates	6

	6 Analysts have issued a price target ACELYRIN 2025 . The average ACELYRIN target price is $10.00. This is 207.69% register free of charge higher than the current stock price. The highest price target is $20.00 515.38% register free of charge , the lowest is $5.00 53.85% register free of charge .
	A rating was issued by 7 analysts: 4 Analysts recommend ACELYRIN to buy, 3 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the ACELYRIN stock has an average upside potential 2025 of 207.69% register free of charge . Most analysts recommend the ACELYRIN stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '23	2024 Estimates
Earnings Per Share $	-5.43	-2.65
	675.71%	51.20%
P/E		negative

2 Analysts have issued a ACELYRIN forecast for earnings per share. The average ACELYRIN <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2023	$-5.43	675.71%
2024	$-2.65 51.20% Unlock
2025	$-2.12 20.00% Unlock
2026	$-2.01 5.19% Unlock
2027	$-1.95 2.99% Unlock
2028	$-1.70 12.82% Unlock

Current
2024	-1.23 1.65% Unlock
2025	-1.54 25.20% Unlock
2026	-1.62 5.19% Unlock
2027	-1.67 3.09% Unlock
2028	-1.91 14.37% Unlock

ACELYRIN...

Discover more stocks with a high price target

Valneva 268.86%

CureVac N.V. 114.53%

Moderna 77.92%

Bavarian Nordic 59.49%

Teamviewer 56.15%

RWE 47.84%

Nel ASA 47.09%

Alibaba Group Holding Ltd 43.74%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now